About 3rd ADDS
3rd ACE Drug Discovery Summit, 2025 provides a platform for scientists, researchers and decision makers from all over the world to debate on the latest scientific advances, trends, current challenges and futuristic advancements in Drug Discovery. The two day conference is designed to maximize collaborations and innovation with pharma and technology presentations, interactive sessions by professionals from industry and academia. The Summit features talks on the cutting edge of the discipline that include latest scientific advancements in the areas of drug discovery, AI, screening automation, high content imaging, disease modelling, cell and gene therapy and more. Summit will be attracting senior strategic decision-makers with top-level speakers, interactive round-tables, knowledge-sharing panel sessions, in-depth workshops and superb networking. Join us at 3rd ACE Drug Discovery, 2025 to meet scientists from around the world and to learn how to move pharma from the bench to the market. We look forward to your contribution!
Why Attend
Solutions at ADDS
🔷 Antibody Engineering
🔷 ADMUPI (Toxicology)
🔷 Covering Biological studies
🔷 Discovery Outsourcing Services
🔷 Drug Discovery Technology Platforms
🔷 High Throughput Screening
🔷 Licensing
🔷 ln licensing/out licensing discovery          projects proprietary technologies
🔷 PK/PD
🔷 Protein identification Services
🔷 Screening and Profiling Services
🔷 Transgenisis Services
🔷 Biochemistry
🔷 Biomarker Validation
🔷 Data Management Technology
🔷 DNA & RNA Analysis
🔷 Gene Expression Profiling Solutions
🔷 Lead Generation
🔷 lmaging/biomarker service/collaboration
🔷 Medicinal Chemistry
🔷 Pharmacogenetic Testing
🔷 Preclinical
🔷 Research & Development
🔷 Structural Biology
🔷 Bio-informatics
🔷 Combinatorial Chemistry
🔷 Digital lmaging Technology
🔷 DNA Sequencing Services
🔷 Genomics
🔷 Lead Optimatisation and Profiling, HTS       Technology
🔷 Molecular Biology
🔷 Pharmacology
🔷 Principal Scientists
🔷 Reagents Technology
🔷 Target identification & Validation
Who Will Attend
🔷 CEO
🔷 Director of Discovery Strategy Portfolio
🔷 Head of DMPK
🔷 Head of R&D Licensing
🔷 Senior Director Discovery Research
🔷 VP of Chemistry
🔷 VP Translational Medicine
🔷 CSO
🔷 Director of Screening & Compound Profiling
🔷 Head of Drug Design
🔷 Head Pharmacology & Toxicology
🔷 Senior Director Function Genomics
🔷 Head Pharmacology & Toxicology
🔷 Director Discovery Alliances
🔷 Executive Director Chemistry
🔷 Head of Molecular Toxicology
🔷 Principal Scientist
🔷 VP & Director of Drug Discovery
🔷 VP Target Discovery & Assessment
ADDS Thought Leaders
LUCIA GUILLAMET
FEDERICA PONTI
Senior Scientist |
Celeris Therapeutics
Â
JOHN NIELAND
CSO |
2N Pharma ApS
Â
JUANA LUCIA FLORES CANDIA
Board Member |
LeadXpro
Â
NORMAN MILLER
Cofounder and CSO |
Kutanios Ltd
MARTA FREITAS
Principal Scientist, Quality Control | Quell Therapeutics
HELEN LOCK
Principal Scientist |
Quell Therapeutics
NAHUEL VILLEGAS
CSO |
Vivan Therapeutics
NAJY ALSAYED
Global Therapeutic Area Head | Menarini Group
WILLIAM DONALDSON
President & CEO | Estrigenix Therapeutics
AGOSTINO MARASCO
Head of Chemistry Italy | Autifony Therapeutics Limited
MARIE-CHRISTINE PARDON
Assistant Professor in Translational Neuroscience | University of Nottingham
BEN DOAK
Head of Innovative Treatments | NHS England
ASIF AHMED
Executive Chairman & CEO | MirZyme Therapeutics
SHAYONI DUTTAÂ
Senior principal Data
scientist | GSK
SONA CHANDRAÂ
President, AI
Pangea Bio
BRENDAN SWAIN
CSO
Shift Bioscience Ltd
ELIOTT HARFOUCHE
Partner | Nodes Advisors AG
CHRYSI SERGAKI
Microbiome Group Leader | Medicines and Healthcare products Regulatory Agency
BENIN JOSEPH
Director Discovery |
Pentagrit
ADELE ROWLEY
Chief Scientific Officer |
Mironid
JANIS TAM
Senior Science Liaison |
Causaly
Â
TOM DEXTER
Senior Vice President
of Business
Development |
Scientist.com
NADIA PILATI
Head of Biology |
Autifony Therapeutics
GIUSEPPE ALVARO
Chief Research Officer |
Autifony Therapeutics
Attendee Breakdown
Attendee Demographics
Agenda
🔷 08:45 – 09:00 Chairman’s Welcome Remarks
🔷 09:00 – 09:30 Presentation no.1:
The rise of deep learning in drug discovery:
The recent applications of deep learning in drug discovery research
Deep learning methods/tools relevant to research.
Future development of deep learning in drug discovery
Buyers 2024 Pharma / Biotech
Our Sponsors
Our Partners
Media Partners
Venue - The Insurance Hall
The Insurance Hall has been the home of the UK conference industry for over 80 years. It is a prestigious and impressive event venue steeped in history, heritage and architectural significance, a hidden gem in one of the City of London’s most decorated buildings. A Grade II listed building formally opened by His Majesty King George V in 1934, The Insurance Hall offers exceptional and flexible event spaces for conferences, receptions, AGMs, business breakfasts, meetings, lunches and dinners for up to 300 people.
SPONSORSHIP OPPORTUNITIES
If you wish to inquire about sponsorship prospects, kindly reach out to:
SPEAKER / DELEGATE OPPORTUNITIES
If you wish to inquire about speaking opportunities, and to book attendee pass, kindly reach out to:
